Canaccord Genuity maintained a Buy rating with a $101.00 price target for Globus Medical (NYSE:GMED) shares, which currently trades at $88.54. The firm's analysis supports the company's ongoing ...

Jefferies analyst reiterated a Buy rating for Globus Medical (NYSE:GMED), with a steady price target of $105.00, following the company's announcement of its plans to acquire Nevro Corp . (NYSE:NVRO), ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Mr. Scavilla said, “I am honored to join the Board and continue to drive forward Dentsply Sirona’s mission of transforming and advancing innovation. As a longtime executive in the healthcare industry, ...

The procedure was a transforaminal lumbar interbody fusion at L4/L5 using Globus Medical's RISE expandable cage and an advanced endoscopy technique. Dr. Kim is a neurological spine surgeon at the USF ...

Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our ...

Audubon, PA-based Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its ...

Analyst Ryan Zimmerman from BTIG maintained a Buy rating on Globus Medical (GMED – Research Report) and keeping the price target at $91.00. Ryan Zimmerman’s rating is based on a combination of ...

collaborative skills. As we navigate an era defined by rapid transformation, the increasing presence of women in leadership roles is proving essential for organizational success. According to Pew ...